GeneralLast reviewed April 2026

Warning Letter(WL)

An official FDA notice of significant regulatory violations requiring prompt corrective action.

Usage Examples

The facility received a Warning Letter for data integrity violations.
The company's stock dropped after the Warning Letter was made public.
Resolution of the Warning Letter required significant CAPA implementation.

What is WL?

A Warning Letter is FDA's official notification that a company has significantly violated FDA regulations. Warning Letters are one of FDA's principal enforcement tools and are posted publicly on FDA's website.

Warning Letters typically follow inspections that identify serious violations such as GMP failures, data integrity issues, product quality problems, or marketing violations. The letter demands prompt corrective action and warns of potential regulatory consequences including seizure, injunction, or prosecution.

Companies must respond to Warning Letters within 15 working days outlining their corrective actions. Inadequate responses may lead to escalated enforcement actions. Warning Letter resolution often takes 6-24 months and may involve re-inspection.

Regulatory Context

This term appears most often in general workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside REGULATORY PROCEDURES MANUAL.

FDAICHHealth Canada

When This Matters

The facility received a Warning Letter for data integrity violations.
The company's stock dropped after the Warning Letter was made public.
Resolution of the Warning Letter required significant CAPA implementation.

Common Mistakes

Relying on generic terminology without mapping to the active jurisdiction context.
Skipping cross-links between terms, tools, and active regulatory references.
Failing to maintain a single source of truth for regulatory definitions internally.

Related Regulations

REGULATORY PROCEDURES MANUAL

How to Respond to an FDA Warning Letter

Develop and submit a comprehensive response to an FDA Warning Letter addressing cited violations and preventing escalation.

1
Acknowledge receipt promptly
Acknowledge the Warning Letter within 15 business days with written confirmation of receipt and intent to respond. Early acknowledgment signals cooperation and opens communication channels.
2
Form a cross-functional response team
Senior management leadership plus Quality, Regulatory, Operations, and often external counsel. The response reflects on the organization's commitment; senior engagement is expected by FDA and visible in the response quality.
3
Investigate each cited violation
For every violation listed: conduct root cause analysis, assess scope (is this a broader issue beyond the cited example?), evaluate product impact, and identify systemic weaknesses that allowed the violation.
4
Develop corrective actions
Immediate corrections for the specific violations plus systemic actions addressing root causes. Include product disposition decisions, process changes, procedural updates, training, equipment/facility changes, and organizational adjustments.
5
Develop preventive actions
CAPA structure applies: actions to prevent recurrence across related processes and products. Systemic fixes carry more weight with FDA than point corrections — demonstrate the quality system will prevent similar issues.
6
Assess product impact
Determine whether marketed products are affected. Recalls, market withdrawals, or production holds may be necessary. Notify customers and document disposition. Transparency with FDA about affected product is critical.
7
Submit the response
Comprehensive written response typically within 15 business days (or by FDA-specified deadline). Include investigation findings, corrective and preventive actions with timelines, evidence of actions already completed, and commitment to follow-up reporting. Follow up with periodic updates as actions close.

Frequently Asked Questions

Form 483 lists observations at inspection conclusion and is not a final determination. Warning Letters come later, after FDA review, and represent official agency findings requiring response.

Yes, FDA publishes Warning Letters on its website. This public disclosure can significantly impact company reputation, stock price, and business relationships.

FDA may escalate to enforcement actions including seizure, injunction, consent decree, import alert, or criminal prosecution. Products may be recalled and facilities may be shut down.